Sanofi faces $250M charge after E. coli vaccine developed with J&J fails Phase 3 trial; study ends early due to insufficient ...

Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline for CNS drugs is ...

New re­search from the Uni­ver­si­ty of North Car­oli­na-Chapel Hill found that No­vo Nordisk’s weight loss drug may help ...

An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities ...

CVS Health ended 2024 as it started, with high medical costs in the company’s insurance business chipping away at its bottom ...

Pfizer secured an eighth indication for its blood cancer drug Adcetris after the FDA approved its use in adults, in ...

AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.

Ab­b­Vie and Xilio Ther­a­peu­tics are part­ner­ing to make “masked” T cell en­gagers, which they hope will be safer than cur­rent­ly avail­able op­tions.

Cerula Care raises $3.7M seed round to support cancer patients' mental health between appointments, selling directly to ...